A 52-year-old man with chronic hypertension presents with left ventricular hypertrophy on echocardiography. His colleague, a 48-year-old bodybuilder, has physiologic hypertrophy of skeletal muscle from resistance training. Which feature best distinguishes pathologic cardiac hypertrophy from physiologic skeletal muscle hypertrophy?

Explanation

## Distinguishing Pathologic vs. Physiologic Hypertrophy ### Key Structural Difference **Key Point:** Pathologic hypertrophy is characterized by activation of the fetal gene program (increased expression of β-myosin heavy chain, atrial natriuretic peptide, and α-skeletal actin) and progressive interstitial fibrosis, whereas physiologic hypertrophy maintains normal gene expression patterns. ### Comparison Table | Feature | Pathologic Hypertrophy (LV) | Physiologic Hypertrophy (Skeletal Muscle) | | --- | --- | --- | | **Gene expression** | Fetal gene reactivation (β-MHC, ANP) | Normal adult gene pattern | | **Collagen deposition** | Increased (fibrosis) | Minimal or absent | | **Function** | Decreased contractility, diastolic dysfunction | Preserved/enhanced strength | | **Reversibility** | Partial (fibrosis persists) | Complete | | **Stimulus** | Maladaptive (pressure/volume overload) | Adaptive (mechanical demand) | | **Outcome** | Heart failure risk | Improved performance | ### Mechanism of Pathologic Hypertrophy 1. Sustained pressure overload (hypertension) or volume overload activates hypertrophic signaling pathways (MAPK, calcineurin) 2. Fetal gene program is re-expressed as a maladaptive response 3. Increased collagen synthesis by cardiac fibroblasts → interstitial fibrosis 4. Impaired diastolic relaxation and eventual systolic dysfunction ### Mechanism of Physiologic Hypertrophy 1. Mechanical stretch from resistance training activates mTOR and PI3K pathways 2. Protein synthesis increases proportionally with demand 3. Gene expression remains normal (adult isoforms) 4. Mitochondrial biogenesis matches increased metabolic demand 5. Function is enhanced, not impaired **High-Yield:** The fetal gene program activation (β-MHC, ANP, α-skeletal actin) is the hallmark that distinguishes pathologic from physiologic hypertrophy and predicts progression to heart failure. **Clinical Pearl:** Pathologic LV hypertrophy in hypertension initially compensates for increased afterload but eventually leads to diastolic dysfunction, then systolic dysfunction and heart failure — a progression that does not occur in physiologic muscle hypertrophy. ### Why Collagen Deposition Matters Progressive fibrosis in pathologic hypertrophy: - Increases myocardial stiffness - Impairs electrical conduction - Reduces coronary perfusion relative to mass - Becomes irreversible even if the original stimulus (e.g., hypertension) is controlled